Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Ocular Therapeutix Inc (NASDAQ: OCUL) was $9.46 for the day, up 3.96% from the previous closing price of $9.1. In other words, the price has increased by $3.96 from its previous closing price. On the day, 3.09 million shares were traded. OCUL stock price reached its highest trading level at $9.595 during the session, while it also had its lowest trading level at $9.04.
Ratios:
Our analysis of OCUL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.14 and its Current Ratio is at 10.22. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.28.
On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $17.
On March 11, 2025, Needham started tracking the stock assigning a Buy rating and target price of $15.Needham initiated its Buy rating on March 11, 2025, with a $15 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 02 ’25 when Waheed Nadia sold 13,861 shares for $8.05 per share. The transaction valued at 111,581 led to the insider holds 206,805 shares of the business.
NADIA K. WAHEED bought 13,861 shares of OCUL for $111,524 on Jun 02 ’25. On May 23 ’25, another insider, Nayak Sanjay, who serves as the Chief Strategy Officer of the company, sold 1,862 shares for $7.17 each. As a result, the insider received 13,351 and left with 281,623 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 1506978048 and an Enterprise Value of 1204844544. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.26 while its Price-to-Book (P/B) ratio in mrq is 5.67. Its current Enterprise Value per Revenue stands at 20.2 whereas that against EBITDA is -5.969.
Stock Price History:
The Beta on a monthly basis for OCUL is 1.48, which has changed by 0.41829085 over the last 52 weeks, in comparison to a change of 0.1185931 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $11.77, while it has fallen to a 52-week low of $5.78. The 50-Day Moving Average of the stock is 16.30%, while the 200-Day Moving Average is calculated to be 11.61%.
Shares Statistics:
OCUL traded an average of 2.13M shares per day over the past three months and 2710280 shares per day over the past ten days. A total of 159.26M shares are outstanding, with a floating share count of 133.28M. Insiders hold about 16.33% of the company’s shares, while institutions hold 74.32% stake in the company. Shares short for OCUL as of 1749772800 were 14421637 with a Short Ratio of 6.78, compared to 1747267200 on 13825192. Therefore, it implies a Short% of Shares Outstanding of 14421637 and a Short% of Float of 9.090000400000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
